Webster Brian Daniel sold $692K of KMTS

Webster Brian Daniel (See Remarks) sold 29,822 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $23.21 ($22.60–$23.92, $0.69M total) across 3 trades over 2026-07-30 to 2026-08-03.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Aug 3, 2026, 11:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may influence sentiment, but it does not introduce new operational, financial, or regulatory information about KMTS.

02

Market read

Traders may monitor KMTS for any clustering of insider sales or abnormal trading activity, but the filing alone is unlikely to drive a sustained move.

03

What to watch

The article does not disclose total insider holdings changes beyond the post-transaction share count, nor does it provide context on prior sales frequency or whether other insiders sold concurrently.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-03 after-hours, covering sales from 2026-07-30 to 2026-08-03

Background

The article is an SEC Form 4 insider transaction filing for Kestera Medical Technologies, Ltd. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows officer/director Webster Brian Daniel sold 29,822 KMTS shares for about $692K across three trades (7/30-8/3).

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on selling or unusual volume rather than expecting a durable repricing.

Evidence & confidence

The filing is a primary-source Form 4, but it provides no new company fundamentals, guidance, or transaction terms beyond the sale size and timing.

Market effects

No sector-level implications; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs; absence of a stated 10b5-1 plan does not automatically imply negative fundamentals.

Key entities

  • KMTS

    Kestra Medical Technologies, Ltd., the company whose insider transaction is reported.

  • Webster Brian Daniel

    Officer and director who sold 29,822 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.